Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease

HEIDELBERG, Germany & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #CHMP--Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announces that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorisation in the European Union for Vevizye®, intended for the treatment of moderate to severe dry eye disease in adult